

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-38. (CANCELLED)

Claim 39. (CURRENTLY AMENDED) A method for developing a therapeutic procedure in a model animal system comprising the steps of:

- a) infecting Tupaia with a human viral pathogen, wherein said pathogen is HCV ~~or a human retrovirus, HIV 1 or HIV 2~~;
- b) carrying out a potential therapeutic procedure ~~to~~ in said infected Tupaia; and
- c) evaluating the effect of said therapeutic procedure on disease manifestations caused by said human viral pathogen in said infected animal.

Claims 40-42. (CANCELLED)

Claim 43. (PREVIOUSLY PRESENTED) The method of claim 39 wherein said therapeutic procedure comprises oral tolerization.

Claims 44-48. (CANCELLED)

Claim 49. (CURRENTLY AMENDED) A method for developing a therapeutic procedure which alleviates clinical manifestations of a disease caused by a human viral pathogen, wherein said pathogen is HCV, HIV 1 or HIV 2 ~~or a human retrovirus~~, comprising the steps of:

- a) infecting Tupaia with a human viral pathogen, wherein said pathogen is HCV, HIV 1 or HIV 2 ~~or a human retrovirus~~;
- b) carrying out a potential therapeutic procedure ~~to~~ in said infected Tupaia; and
- c) evaluating the effect of said therapeutic procedure on clinical manifestations caused by said human viral pathogen.

Application No. 10/042,711
Paper Dated: March 25, 2009
In Reply to USPTO Correspondence of March 18, 2009
Attorney Docket No. 5795-083977

Claim 50. (PREVIOUSLY PRESENTED) The method of claim 49 wherein said therapeutic procedure comprises oral tolerization.

Claim 51. (CURRENTLY AMENDED) The method of claim 49 wherein said clinical manifestations are secondary disease manifestations of said infection and wherein said disease manifestations are inflammation, fibrosis, induced auto-immunity, apoptosis or a combination thereof.

Claims 52-57. (CANCELLED)

Claim 58. (CURRENTLY AMENDED) A method for developing a therapeutic procedure in a model animal system comprising the steps of:

- a) infecting Tupaia with a human viral pathogen;
- b) carrying out a potential therapeutic procedure to in said infected Tupaia; and
- c) evaluating the effect of said therapeutic procedure on secondary disease manifestations caused by said human viral pathogen in said infected Tupaia wherein said disease manifestations are inflammation, fibrosis, induced auto-immunity, apoptosis or a combination thereof.

Claim 59. (CANCELLED)

Claim 60. (CURRENTLY AMENDED) The method of claim 58 wherein said human viral pathogen is a human retrovirus HIV 1, HIV 2, HTLV-1 or HTLV-2.

Claim 61. (CANCELLED)

Claim 62. (PREVIOUSLY PRESENTED) The method of claim 58 wherein said human viral pathogen is HBV or HCV.

Claim 63. (PREVIOUSLY PRESENTED) The method of claim 58 wherein said therapeutic procedure comprises oral tolerization.

Claims 64-68. (CANCELLED)

Claim 69. (CURRENTLY AMENDED) A method for developing a therapeutic procedure which alleviates secondary clinical manifestations of a disease caused by a human viral pathogen comprising the steps of:

- a) infecting Tupaia with a human viral pathogen;
- b) carrying out a potential therapeutic procedure to in said infected Tupaia; and
- c) evaluating the effect of said therapeutic procedure on clinical manifestations caused by said human viral pathogen in said infected Tupaia wherein said clinical manifestations are inflammation, fibrosis, induced auto-immunity, apoptosis or combination thereof.

Claim 70. (CANCELLED)

Claim 71. (PREVIOUSLY PRESENTED) The method of claim 69 wherein said human viral pathogen is a human retrovirus.

Claim 72. (PREVIOUSLY PRESENTED) The method of claim 71 wherein said human retrovirus is HIV 1, HIV 2, HTLV-1 or HTLV-2.

Claim 73. (PREVIOUSLY PRESENTED) The method of claim 69 wherein said human viral pathogen is HBV or HCV.

Claim 74. (PREVIOUSLY PRESENTED) The method of claim 69 wherein said therapeutic procedure comprises oral tolerization.